INTRODUCTION
The treatment of metastatic melanoma has substantially transformed within the last decade, with improvement in outcomes with multiple approved immunotherapies targeting programmed cell death protein 1 (PD-1) and cytotoxic Tlymphocyte-associated protein 4 (CTLA4), as well as viral-based immunotherapy. [1] [2] [3] [4] These immunotherapies have produced durable responses in a substantial percentage of patients, with combinations demonstrating even higher activity. Similarly, therapy targeted at the common activating V600 mutations in BRAF have proven effective, with high response rates, although responses generally are not as durable as with immunotherapy. 5, 6 Nevertheless, not all patients respond to these therapies; in particular, patients with BRAF wild-type who progress through initial immunotherapy often are left without a standard alternative second-line treatment. In those instances, in the absence of available clinical trials, providers still use chemotherapy, with its modest activity, given the absence of other, perhaps more preferable, alternatives.
Response rates to single-agent chemotherapy in patients with melanoma are low (15%-20%) and short-lived, with no impact reported on overall survival (OS). 7 Hodi et al studied carboplatin and paclitaxel at a dose of 175 mg/m 2 (area under the curve, 7.5) on a 21-day cycle in 15 chemotherapy-naive patients. 8 A response rate of 20% was observed, with 47% of patients achieving stable disease. Toxicities were mostly hematologic. Zimpfer-Rechner et al randomized patients to paclitaxel with or without carboplatin. The median progression-free survival (PFS) was reported as 8 weeks in both treatment arms. 9 Finally, a retrospective series by Rao et al reported a 26% response rate with a median time to disease progression of 3 months. 10 A phase 3 study confirmed the 4-month PFS for the combination of carboplatin and paclitaxel in patients with metastatic melanoma, 11 which was found to be superior to historic numbers of 1.7 months in a large meta-analysis. 12 The combination of carboplatin and paclitaxel is listed in National Comprehensive Cancer Network guidelines for treatment in second-line or later lines of therapy. 13 Perez et al 14 examined the combination of carboplatin, paclitaxel, and bevacizumab (CPB) for the treatment of patients with AJCC 6th edition stage IV unresectable melanoma, reporting a median PFS of approximately 6 months, with an OS of 12 months in the preimmunotherapy and targeted therapy era. The most common severe (grade 31) toxicities reported were neutropenia (49%), leukopenia (34%), thrombocytopenia (8%), anemia (8%), hypertension (6%), fatigue (6%), and nausea (6%).
We hypothesized that the addition of everolimus would improve the clinical outcomes of the CPB regimen. First, given the tremendous complexity and redundancy in metabolic pathways in melanoma, aberrant pathways must likely be targeted in multiple ways to provide optimal inhibition. Multiple studies have demonstrated the adverse effects of vascular endothelial growth factor (VEGF) expression in melanoma, including its association with worsened prognosis, 15 chemotherapy resistance, 16 and immunosuppression. 17 Bevacizumab is a monoclonal antibody against VEGF-A, and as such is effective at reducing VEGF-A levels but not VEGF-C, which is important in lymphangiogenesis and possibly VEGF-induced immune suppression. 18 Mammalian target of rapamycin (mTOR), the target of everolimus, can induce expression of VEGF-C, and inhibition of mTOR with rapamycin has been shown to potently reduce VEGF-C expression in a murine skin flap model 19 and murine tumor xenografts. 20 A phase 2 study combining everolimus and bevacizumab in patients with metastatic melanoma demonstrated a PFS of 4 months and good tolerability. 21 We constructed a randomized, phase 2 study to explore the CPB combination with (CPBE) and without everolimus to explore the activity of the combination. Unlimited targeted therapy and immunotherapy were allowed before enrollment.
MATERIALS AND METHODS

Study Design
This North Central Cancer Treatment Group (NCCTG; now part of the Alliance) clinical trial N0879 was a randomized phase 2 trial of 149 patients with unresectable stage IV melanoma that was performed to assess the addition of everolimus to the CPB combination. The study was conducted in accordance with the Mayo Clinic Cancer Center Data and Safety Monitoring Board (MCCC DSMB), the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0), and the Mayo Clinic institutional review board. All patients provided written informed consent before any study procedure. This trial is registered at ClinicalTrials.gov (identifier NCT00976573).
Study Population
Patients were enrolled from May 2010 to May 2014. The study was available to all eligible patients, regardless of race, sex, or ethnic origin. Inclusion criteria required histologic proof of stage IV malignant melanoma not amenable to surgery, measurable disease, a life expectancy of 4 months, age 18 years, adequate blood counts and organ function, an Eastern Cooperative Oncology Group performance score of 0 to 1, and 1 prior chemotherapy-based regimen for metastatic melanoma (no prior taxane-based regimens). Prior adjuvant non-taxane-based chemotherapy and/or adjuvant immunotherapy were allowed and there was no limit on the number of prior biologic, immunologic, or targeted therapies. Exclusion criteria were prior mTOR-directed or VEGF-directed therapy, brain metastases, major comorbidities, or contraindications to bevacizumab.
Random Assignment
A 12-patient "run-in" phase (6 eligible patients were randomized to each of the regimens) was conducted to assess for any unexpected toxicities from the addition of everolimus to the CPB regimen. Full study enrollment was suspended until each of these 12 patients was followed for at least 2 cycles of treatment to monitor for the development of dose-limiting toxicities. Once the study was open to enrollment, a dynamic allocation procedure allocated an equal number of patients to 1 of the 2 treatment regimens. The stratification factors that were balanced between the 2 treatment arms were M classification (M1a, M1b, and M1c), elevated lactate dehydrogenase (yes vs no), and prior cytotoxic chemotherapy for metastatic disease.
Treatment Protocol
Patients were randomized to treatment arm A (CPB) with carboplatin at an area under the curve of 5 administered intravenously (iv) on day 1 and repeated every 28 days; paclitaxel at a dose of 80 mg/m 2 iv on days 1, 8, and 15; and bevacizumab at a dose of 10 mg/kg iv on days 1 and Original Article 15 ( Fig. 1) . Treatment arm B (CPBE) was the same as shown for arm A, with the above regimen and everolimus at a dose of 5 mg on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 repeated every 28 days. Due to neutropenia and other related toxicities, the everolimus dose was decreased to 5 mg three times weekly (addendum 5, made October 1, 2010). With the initial dose of everolimus, 4 patients experienced grade 3 neutropenia, 4 patients developed grade 3 leukopenia, and 1 patient had grade 2 myalgia. To maintain the starting doses of all therapies on CPBE, the starting dose of everolimus was reduced to an initial dose of 5 mg three times weekly. This was chosen due to the halflife of everolimus (25-30 hours) and, in addition, there is demonstrated evidence of continued successful target inhibition in a patient whose everolimus dose was 5 mg three times weekly when used in a 3-drug combination that was well tolerated. 22 In addition, the maximum carboplatin dose for newly enrolled patients was capped at 750 mg.
Outcome Measures
The primary endpoint was PFS with the addition of everolimus to the CPB combination. The secondary objectives were to estimate the confirmed tumor response rate, estimate the distribution of OS time, and assess the safety profile of each of the treatment regimens. We examined the impact of common genetic variants and tumor site origin on outcomes from therapy.
DNA Sequencing Analysis
Archived paraffin tumor biopsy material was requested for all patients from either primary tumors or metastases. Hematoxylin and eosin-stained slides were reviewed by 2 pathologists for tumor amount and percentage of tumor nuclei, and DNA then was extracted using the QIAamp DSP DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). A clinical 50-gene hotspot polymerase chain reactionbased MiSeq Next-Generation panel (Illumina, San Diego, California) was analyzed on the extracted DNA at Mayo Medical Laboratories by one of the authors (K.R.). Melanoma-relevant genes examined included BRAF, NRAS, C-kit, GNAQ, and GNA11. Identified known mutations were coded as mutant versus wild-type. The sequenced data then were analyzed at Mayo Medical Laboratories and alignments visualized in Alamut (Interactive Biosoftware, Rouen, France). There were 114 patients with sufficient tissue for analysis.
Statistical Analysis
The design had a 1-sided significance level of a 5 .10 with 83% power to detect a HR of 0.67 (hazard ratio). This was an intention-to-treat (ITT) analysis in which all eligible patients were analyzed by the treatment arm to which they were randomized for the primary outcome.
Of the 149 patients enrolled in the study, 1 patient was later determined to be ineligible. This left 148 patients in a modified ITT analysis set (75 in the CPB arm and 73 in the CPBE arm). Of these 148 patients, 6 patients withdrew from participation before receiving any study treatment (71 were treated in each arm).
OS was defined as the time from registration until death due to any cause. The distributions of PFS and OS were estimated using the Kaplan-Meier method. A stratified log-rank test and Cox partial likelihood score test assessed whether the distribution of PFS or OS times differed with respect to the treatment regimen, having adjusted for M classification (M1a, M1b, and M1c) and prior chemotherapy in the metastatic setting. A confirmed tumor response was defined as a complete response (CR) or partial response (PR) (as per Response Evaluation Criteria In Solid Tumors [RECIST] criteria [version 1.1]), and the percentage of tumor responses was estimated by the number of confirmed tumor responses divided by the total number of evaluable patients with a 95% confidence interval (CI). When measuring treatment response, a subsequent scan was obtained 8 weeks after initial documentation of an objective status of either CR or PR. In the case of stable disease, follow-up measurements must have met the stable disease criteria at least once after study entry at a minimum interval of 8 weeks.
The Cancer Therapy Evaluation Program of the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) was used for the reporting of adverse events. The study team reviewed the toxicities, which were submitted for consideration by the MCCC DSMB, CTEP, and the institutional review board. The information was submitted to the MCCC DSMB every 6 months until all patients were off study treatment. If > 30% of the patients developed a grade 3 1 hemorrhage, febrile neutropenia, grade 4 neutropenia lasting 5 days, anemia, a platelet count <25,000, or grade 4 1 nonhematologic toxicity and these events were considered to be likely related to treatment, enrollment to that regimen would be suspended. Adverse events were reported for all adverse events and attribution levels of possibly or greater-related. Reports also designated patients randomized to CPBE into those randomized before and after the everolimus dosing reduction addendum (addendum 5).
RESULTS
Population and Demographics
There were 148 eligible patients randomized to 2 treatment arms: 75 patients in the CPB arm and 73 patients in the CPBE arm. Although 6 patients cancelled before receiving any study treatment (leaving 71 patients total in each arm), there was an ITT analysis for the primary endpoint. Patients were similar in each treatment arm (Table 1) , with the exception of patients in the CPB arm having a greater percentage of males compared with the CPBE arm (72% vs 54.8%; P 5 .03). Of the patients enrolled, 38.1% had received prior ipilimumab therapy, 21.2% had received prior chemotherapy, and 4.1% had received vemurafenib. In addition, 19.5% of patients had proven BRAF mutations. The most common primary tumor site was the trunk at 23.3%. There was a large percentage of patients enrolled in the study with uveal melanoma as their primary tumor site (17.8%). Of the 143 patients who underwent treatment, 27 were alive at a median follow-up of 38.5 months (range,
Primary Endpoint of PFS
The primary endpoint for this trial was PFS. Time to PFS was defined as the number of days between randomization until documentation of disease progression or death. Using an ITT analysis, there were 142 patients (71 who were able to receive treatment in each arm). The hazard ratio (HR) was 1.17 (95% CI, 0.84-1.65; P 5 .35), which indicated no difference with regard to PFS between the 2 treatment arms (Fig. 2) . The median PFS times were 5.6 months and 5.1 months, respectively, for the CPB and CPBE arms.
There was no significant difference in PFS noted for females versus males. Females (52 patients) had a PFS of 4.9 months and males (90 patients) had a PFS of 5.6 months (P 5 .78). A large number of patients with uveal melanoma were included in the study, potentially confounding the results in melanoma of cutaneous origin. Therefore, a sensitivity analysis was performed excluding patients with uveal melanoma for the primary endpoint of PFS. Of the total of 122 patients, the median PFS times were 5.5 months and 5.4 months, respectively, for the CPE and the CPBE arms (HR, 1.12; 95% CI, 0.77-1.62).
Secondary Endpoints
For OS, there was no significant difference noted between the 2 treatment arms. The median OS times were 14.5 months and 11.2 months, respectively, for the CPB and CPBE arms, with an HR of 1.20 (95% CI, 0.83-1.73) (Fig. 2) .
Original Article
In the CPB arm, there were 10 confirmed responses with 2 CRs and 8 PRs. Among patients in the CPBE arm, there was 1 CR and 18 PRs (P 5 .22).
Drug Exposure
Overall, there was a trend toward dose reduction in the CPBE treatment arm compared with the CPB arm. There were fewer dose modifications after the addendum 5 dose modification when comparing the first 3 cycles of chemotherapy. Of 142 patients, 104 (73.2%) had at least 1 dose modification during their treatment. In the CPB arm, 47 of 71 patients (66.2%) had a dose reduction compared with 57 of 71 patients in the CPBE arm (80.3%). This difference was not statistically significant (P 5 .06). In the CPBE arm, 18 of 20 patients (90.0%) had a dose reduction before the addendum, and 38 of 51 patients (74.5%) had a reduction after the addendum (P 5 .20). With only the first 3 rounds of chemotherapy, there was at least 1 dose modification among 14 of 20 patients in the CPBE arm (70.0%) before the addendum compared with 30 of 51 patients (58.8%) after the addendum (P 5 0.38). However, there was no difference in the doses before and after addendum 5 on the CPBE arm.
Safety Outcomes
The most common adverse events include neutropenia, leukopenia, thrombocytopenia, hypertension, fatigue, and anorexia. Grade 3 1 hematologic adverse events were more frequent in the preaddendum CPBE group compared with the postaddendum group (65.0% in the preaddendum group and 60.8% in the postaddendum group). The frequency of grade 3 1 adverse events in the CPBE arm before addendum 5 was 85.0% and, despite the decrease in the dose of everolimus, the postaddendum frequency was 88.2%, possibly due to early dose reduction in the preaddendum patients for hematologic toxicities. In addition, toxicity was higher for patients in the CPBE arm after the addendum versus the CPB arm for grade 3 1 for all adverse events regardless of attribution. The frequency of grade 4 1 adverse events for patients in the CPBE arm after the addendum was 23.5% (preaddendum frequency, 15.0%) and that in the CPB arm was 18.0% (Table 2) .
Uveal Melanoma
There were 25 evaluable patients with uveal melanoma in the current study, which is a relatively large number of patients for this rarer disease. There also were 2 patients with mucosal melanoma. The median PFS for the patients with uveal/mucosal melanoma in the CPB arm was 5.6 months compared with 5.6 months for all other disease groups (P 5 .68). Among patients in the CPBE arm, the median PFS was 4.5 months for the patients with uveal/ mucosal melanoma and 5.5 months for patients with any other disease site (P 5 .25). If the treatment arm was ignored, and only patients with uveal melanoma were included (25 patients), the median PFS was 5.4 months for patients with uveal melanoma versus 5.5 months for patients with all other disease sites (P 5 .53) (See Supporting Information Fig. 1 ). The was 1 PR noted in the CPB arm among patients with uveal melanoma (1 of 16 patients; 6%). There were no responses reported in the CPBE arm (0 of 10 patients; 0%).
BRAF Status Analysis
BRAF status was analyzed in 114 patients. We compared outcomes in each treatment arm for patients with known BRAF mutant tumors versus those with known wild-type tumors. There was no difference in PFS or OS noted in the CPE arm (see Supporting Information Fig. 2 ). However, for the CPBE arm, patients with BRAF mutations were found to have a superior PFS compared with patients with BRAF wild-type (median PFS, 6.0 months vs 3.9 months; P 5 .039). However, no survival benefit was observed in the BRAF wild-type group (median survival, 11.2 months vs 9.5 months; P 5 .793).
Extraordinary Patients
There were 2 patients on the CPBE arm with exceptional outcomes. One patient, a 30-year-old woman with metastases to the lung, received treatment for 35 cycles. At the time of last follow-up, the patient still was alive after 52.5 months of follow-up. The patient had received prior immunotherapy (granulocyte-macrophage colonystimulating factor) and prior radiotherapy. This patient achieved a confirmed CR before going off treatment due to disease progression. BRAF was not tested, and no tissue was available for analysis.
Another patient, a 61-year-old female with liver metastases, received treatment for 30 cycles. The patient was still alive after 41.4 months of follow-up. This patient was BRAF wild-type. She received prior immunotherapy (ipilimumab) and had a confirmed PR with CPBE before going off treatment due to disease progression.
Because of these notable outcomes, a subset analysis of patients who received ipilimumab or any immunotherapy before enrollment was performed. Unfortunately, it demonstrated no notable differences in outcome from that of other patients (data not shown).
DISCUSSION
The current study demonstrated no improvement in PFS with the addition of everolimus to the combination of CPB. Reasons for this may include inactivity of the agent in combination and the inability to give the full dose of everolimus due to toxicity, which was predominantly cytopenias. Other studies also have demonstrated the difficulty in maintaining the dose strength of everolimus in combination with chemotherapies that cause cytopenias. 22 The OS curve appeared to trend toward a better outcome for patients treated with CPB, although it did not reach statistical significance. The lack of meaningful difference in PFS between the treatment arms suggests that treatment did not notably impact this outcome, and therefore the underlying reason for any difference is uncertain, although the lower toxicity in the CPB arm may influence these curves.
Although a negative study, there were some interesting findings in the current analysis. First, 2 patients on the everolimus combination arm performed exceptionally well, receiving >30 cycles of therapy. Both had received prior immunotherapy, with ipilimumab and granulocytemacrophage colony-stimulating factor, respectively. However, subset analysis of prior ipilimumab and immunotherapy exposure demonstrated no difference in outcome compared with all other patients. In addition, the overall PFS of >5 months in both treatment arms suggests some antitumor activity of the CPB combination. A prior randomized phase 2 study of the combination revealed a PFS of 4.4 months versus 2.7 months for carboplatin and paclitaxel alone (HR, 0.52), although the likely underpowered trial did not reach statistical significance. 23 Of particular interest is the relatively large number of patients with uveal melanoma. There was a relatively large number of such patients enrolled, most likely due to other trial options and intercurrent approvals for cutaneous melanoma (see Supporting Information Fig. 3 ), including BRAF inhibitors and immunotherapy, which likely also impacted the frequency of BRAF-mutant patients enrolled. Patients with uveal melanoma had efficacy outcomes similar to those of patients with melanoma of cutaneous origin, with a PFS of >5 months regardless of treatment arm (95% CI, 3.8-9.1 months). This is in distinction to the recent report of antiprogrammed cell death protein 1 therapy, with a median PFS of 2.6 months (95% CI, 2.4-2.8 months) and an OS of 7.6 months. 24 Similarly, a phase 3 trial was launched for the MEK inhibitor selumetinib for patients with uveal melanoma versus chemotherapy given an initial increase in the median PFS from 7 to 16 weeks. 25 However, the phase 3 trial was discontinued earlier this year due to failure to meet endpoints. In addition, a randomized phase 2 study of the MEK inhibitor trametinib with and without the Akt inhibitor GSK2141795 was negative for the combination, with a median PFS of <16 weeks in both treatment arms. A recent study of tumorinfiltrating lymphocyte therapy in patients with uveal melanoma reported a response rate of >30%; however, the PFS was not reported. 26 Although comparisons between studies are difficult, the CPB combination appears to be a reasonable option for patients with uveal melanoma given the absence of activity among alternatives.
In the current study, patients with BRAF mutations in the CPBE arm had improved PFS compared with patients in the CPB arm (6.0 months vs 3.9 months, respectively). There is some rationale as to BRAF-mutant melanomas having an activated mTOR pathway, with the latter representing a resistance mechanism to targeted therapy. For example, in an in vitro study, the combination of BRAF inhibitors plus mTOR inhibition in vitro enhanced cell growth inhibition while decreasing the expression of proteins involved in mTOR activation, thus overcoming the resistance of mutated cells to BRAF inhibition. 27 In patients with brain tumors, mTOR activation has been shown to be increased in those with BRAF-mutant tumors, as measured through expression of pS6. 28 In a phase 1 clinical trial of vemurafenib and everolimus, approximately 65% of patients with BRAF-mutant advanced cancers responded to this combination chemotherapy, which although also being safe and well-tolerated, 29 has a response rate comparable to response rates of vemurafenib alone. Therefore, the results of the current study suggesting an improved PFS with the addition of everolimus in patients with BRAF-mutant tumors are of interest, and merit further study, although the benefit appears mostly due to the underperformance of CPBE in the patients with BRAF wild-type (see Supporting Information Fig. 2 ).
Further use of chemotherapy combinations for patients with melanoma will likely decrease over time as immunotherapy options increase in efficacy. However, until all patients with metastatic melanoma achieve durable responses with immunotherapy or targeted therapy, cytotoxic chemotherapy will likely remain an option for some patients with refractory disease.
Conclusions
The addition of everolimus to the CPB combination increased toxicity, but did not increase efficacy among patients with metastatic melanoma.
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